The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
News|Articles|March 2, 2014
Tablet Press with Fastest-in-Class Changeover
Tablet Press with Fastest-in-Class Changeover
Advertisement
At INTERPHEX Fette Compacting America will showcase the FE35 Tablet Press, which offers unprecedented productivity and flexibility, and best-in-class changeover time. The single-rotary tablet press can be fitted with up to 51 stations to produce up to 367,000 tablets/hr. The FE35 is clad in easily-detachable, FDA certified polymer panels, and offers 360-degree access. All product contact parts are stainless steel.
Fette Compacting America, Rockaway, NJ
•
INTERPHEX Booth # 2505C
Advertisement
Related to this article
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
2
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
3
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
4
Ask the Expert: Post-Approval Changes
5